90 results about "Anti-HIV Agent" patented technology

The present invention relates to a nitrogen-containing fused ring compound represented by the following formula [I]wherein each symbol is as defined in the specification, or a pharmaceutically acceptable salt thereof, and an anti-HIV agent containing such compound. The compound of the present invention has an HIV integrase inhibitory activity, and is useful as an agent for the prophylaxis or treatment of AIDS, or as an anti-HIV agent. In addition, by the combined use with other anti-HIV agents such as a protease inhibitor, a reverse transcriptase inhibitor and the like, it can be a more effective anti-HIV agent. Because it shows integrase-specific high inhibitory activity, the compound can be a pharmaceutical agent safe on human body, which causes only a fewer side effects.

The present invention relates to a nitrogen-containing fused ring compound represented by the following formula [I]wherein each symbol is as defined in the specification, or a pharmaceutically acceptable salt thereof, and an anti-HIV agent containing such compound. The compound of the present invention has an HIV integrase inhibitory activity, and is useful as an agent for the prophylaxis or treatment of AIDS, or as an anti-HIV agent. In addition, by the combined use with other anti-HIV agents such as a protease inhibitor, a reverse transcriptase inhibitor and the like, it can be a more effective anti-HIV agent. Becuae it shows integrase-specific high inhibitory activity, the compound can be a pharmaceutical agent safe on human body, which causes only a fewer side effects.

The present invention relates to a combination therapy for treating an HIV infection or inhibiting integrase comprising (S)-6-(3-Chloro-2-fluorobenzyl)-1-(1-hydroxymethyl-2-methylpropyl)-7-methoxy-4-oxo-1,4-dihydroquinoline-3-carboxylic acid (“Compound A”) or a pharmaceutically acceptable solvate or salt thereof in combination with at least one other anti-HIV agent. In some embodiments of the present invention, the other anti-HIV agents are chosen from reverse transcriptase inhibitors and protease inhibitors. In certain embodiments of the present invention, the other anti-HIV agents are chosen from AZT, 3TC, PMPA, efavirenz, indinavir, nelfinavir, a combination of AZT / 3TC, and a combination of PMPA / 3TC. Since Compound A has a high inhibitory activity specific for integrases, when used in combinations with other anti-HIV agents it can provide a combination therapy with fewer side effects for humans.

Methods are provided for screening natural and synthetic anti-HIV agents using recombinant cells that are rendered susceptible to productive infection of various strains, subtypes or clades of HIV from both laboratory and clinical isolates. The method comprises: taking a culture of recombinant cells in which at least one of the recombinant cells comprises a reporter sequence comprising a reporter gene whose expression is regulated by a protein specific to HIV, and a heterologous sequence which encodes CD4 and one or more additional cell surface receptors, wherein the heterologous sequence expresses CD4 and the one or more additional cell surface receptors at elevated levels as compared to the cell in the absence of expression by the heterologous sequence such that productive infection of the recombinant cell by HIV is achieved, which is defined by HIV viral replication and the infection of non-infected cells in the culture of the recombinant cells; contacting the cell culture with a sample containing HIV; adding a tester agent to the cell culture; and detecting a change in a level of expression of the reporter gene in the cells in the culture.

The present invention provides compounds of the general structure: which are substituted at the 3 and 28 positions, along with pharmaceutical formulations containing the same and methods of treating viral infections employing the same.

The present invention provides compounds of the general structure:which are substituted at the 3 and 28 positions, along with pharmaceutical formulations containing the same and methods of treating viral infections employing the same.

An anti-HIV agent containing, as an active ingredient, a 4-oxoquinoline compound represented by the following formula [I]wherein each symbol is as defined in the specification, or a pharmaceutically acceptable salt thereof. The compound of the present invention has HIV integrase inhibitory action and is useful as an anti-HIV agent for the prophylaxis or therapy of AIDS. Moreover, by a combined use with other anti-HIV agents such as protease inhibitors, reverse transcriptase inhibitors and the like, the compound can become a more effective anti-HIV agent. Since the compound has high inhibitory activity specific for integrases, it can provide a safe pharmaceutical agent with a fewer side effects for human.

Disclosed is a skin or oral composition comprising an anti-bacterial agent, which produces no adverse side effect caused by a steroid contained therein. The composition comprises: 0.01 to 4.5 mass% of at least one component selected from the group consisting of an anti-bacterial agent, an anti-viral agent, an anti-HIV agent, a non-nucleoside reverse transcriptase inhibitor, an anti-cancer agent for external application, and a bactericidal agent; 0.01 to 4.5 mass% of a non-steroidal anti-inflammatory agent; 0.001 to 4.5 mass% of a steroidal anti-inflammatory agent; and 0.001 to 10 mass% of a super-water-absorbent polymer or a cellulose derivative.